SCHEDULE 13G/A: Perceptive Advisors Maintains 9.99% Stake in Traws Pharma

Perceptive Advisors and affiliates report a 9.99% beneficial ownership stake in Traws Pharma, Inc., primarily through exercisable warrants, as detailed in their latest Schedule 13G filing.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, "Reporting Persons") beneficially own 886,887 shares of Traws Pharma, Inc. Common Stock.
• This ownership represents 9.99% of Traws Pharma's outstanding Common Stock, based on 7,990,867 shares outstanding as of November 10, 2025.
• The stake is primarily held through 393,877 Pre-Funded Warrants and 979,815 Common Warrants, which are immediately exercisable for shares of Common Stock by the Master Fund.
• A beneficial ownership limitation prevents the Reporting Persons from exercising warrants if it would result in ownership exceeding 9.99% of the outstanding shares.
• Perceptive Advisors serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors.
• The Reporting Persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of Traws Pharma, Inc.

Sentiment

Score: 6

Explanation: A routine disclosure of a significant, but passive, institutional stake. While not inherently positive or negative for the company's operational performance, the continued presence of a specialized investor is generally viewed favorably by the market.

Positives

• Perceptive Advisors, a specialized life sciences investment firm, maintains a significant 9.99% beneficial ownership in Traws Pharma, indicating continued interest in the company's prospects.

Negatives

• The beneficial ownership limitation restricts the Reporting Persons from exercising additional warrants if it would result in ownership exceeding 9.99% of Traws Pharma's outstanding shares, limiting their potential for increased direct influence.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Traws Pharma, Inc. It is a disclosure of an investor's current ownership stake.

Industry Context

Perceptive Advisors is a prominent investment firm with a strong focus on the life sciences sector. Their continued significant stake in Traws Pharma suggests an ongoing belief in the company's potential within the broader biotech and pharmaceutical industry, aligning with their investment strategy.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's passive stake in the company, which may influence investor sentiment.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses the continued passive beneficial ownership of 9.99% of Traws Pharma, Inc. by Perceptive Advisors and its affiliates. While the presence of a specialized life sciences investor like Perceptive Advisors can be a positive signal, this routine disclosure does not contain new material information regarding Traws Pharma's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should consider this information as part of a broader analysis of the company's fundamentals and market position.

Keywords

Traws Pharma, Perceptive Advisors, Joseph Edelman, Schedule 13G, beneficial ownership, common stock, warrants, institutional investor, biotech, pharmaceutical